Remedy Entertainment Pledges Purely Human Creativity for Upcoming ‘Control Resonant’
In a significant statement for the gaming industry, Remedy Entertainment’s interim CEO, Markus Mäki, has confirmed that their highly anticipated adventure game, Control Resonant, will be developed entirely through human creativity and ingenuity. This assurance directly addresses concerns about the burgeoning use of generative artificial intelligence (GenAI) in game development, a topic that has sparked considerable debate among players and developers alike.
During a recent company earnings call, Mäki elaborated on the studio’s commitment to player value, emphasising the importance of crafting experiences that genuinely enhance gameplay. While acknowledging that various departments within Remedy are exploring AI tools with “varied interest,” Mäki was unequivocal: GenAI is not currently being integrated into their game development pipeline, and Control Resonant will remain completely free of it from conception through to its final stages.
Mäki, however, adopted a pragmatic outlook regarding the future of GenAI at Remedy. He did not entirely dismiss the possibility of its adoption, stating that the company is actively monitoring technological advancements. The decision to potentially incorporate AI in the future will hinge on whether such tools are ethically sound, demonstrably add value for players, and are embraced by their development teams. “Making far-reaching promises about the future is pretty hard at this point,” Mäki remarked. “We are actively following the development [of GenAI] and seeing if there is anything that is really ethically in the right place, and is something that can add player value and that our teams want to use. Then, of course, that’s an easier decision.” This measured approach underscores Remedy’s dual focus on player satisfaction and ethical considerations.
The GenAI Conundrum in Game Development
Mäki’s stance resonates with a broader sentiment within the games industry. While investors often express enthusiasm for technologies perceived to offer efficiency and cost savings, the practical application of GenAI in game development presents numerous challenges. Beyond the immediate concerns of copyright, a significant hurdle is player reception. Many gamers, particularly those invested in established intellectual properties, are vocal in their criticism of GenAI, viewing it as a potential detractor from game quality and a devaluation of human artistic input.
A recent, stark example of this backlash occurred with Larian Studios, the acclaimed developer behind Baldur’s Gate 3. CEO Swen Vincke had previously shared his optimism about GenAI’s potential to streamline future projects, such as the Divinity series. This announcement was met with a torrent of criticism from players who feared the erosion of human talent and a departure from the studio’s core values of creativity and passion. The outcry was so significant that Vincke was compelled to issue a public statement confirming Larian would cease using GenAI tools for concept art development.
It is highly probable that Remedy Entertainment, like many other studios observing these public reactions, is acutely aware of how the integration of GenAI can influence player perception and enthusiasm for upcoming titles. The industry is watching closely as developers navigate this complex technological landscape.
A New Leader on the Horizon for Remedy
Coinciding with the discussion on GenAI, the same earnings call revealed another significant development for Remedy Entertainment: the appointment of Jean-Charles Gaudechon as the studio’s new CEO, effective in March. Gaudechon brings a wealth of experience from leadership roles at Electronic Arts and CCP Games, where he was instrumental in managing profit and loss.
Henri Österlund, Chairman of the Board of Directors, expressed his confidence in the incoming CEO. “I am delighted to announce the appointment of Jean-Charles (JC) Gaudechon to lead Remedy into a phase of profitable growth,” Österlund stated. “Under JC’s leadership, we are well-positioned to significantly accelerate growth, guide Remedy towards greater independence through self-publishing, and deliver sustained value to our players, partners and shareholders.”
Gaudechon steps into the role of permanent CEO, succeeding Mäki, who has been serving as interim CEO. This transition follows the departure of Tero Virtala, who concluded his nine-year tenure leading the company in 2025. While it remains to be seen if Gaudechon shares Mäki’s cautious approach to GenAI, the industry will undoubtedly be keen to hear Remedy’s future strategies as these leadership changes solidify. The commitment to human creativity in Control Resonant signals a strong foundation for this new era.
